Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Low-density lipoprotein receptor-related protein-1 (LRP1) is the main cell surface receptor involved in brain and systemic clearance of the Alzheimer's disease (AD) toxin amyloid-beta (Aβ). In plasma, a soluble form of LRP1 (sLRP1) is the major transport protein for peripheral Aβ. LRP1 in brain endothelium and mural cells mediates Aβ efflux from brain by providing a transport mechanism for A across the blood-brain barrier (BBB). sLRP1 maintains a plasma ‘sink’ activity for Aβ through binding of peripheral Aβ which in turn inhibits re-entry of free plasma Aβ into the brain. LRP1 in the liver mediates systemic clearance of Aβ. In AD, LRP1 expression at the BBB is reduced and Aβ binding to circulating sLRP1 is compromised by oxidation. Cell surface LRP1 and circulating sLRP1 represent druggable targets which can be therapeutically modified to restore the physiological mechanisms of brain Aβ homeostasis. In this review, we discuss how increasing LRP1 expression at the BBB and liver with lifestyle changes, statins, plant-based active principles and/or gene therapy on one hand, and how replacing dysfunctional plasma sLRP1 on the other regulate Aβ clearance from brain ultimately controlling the onset and/or progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“…al., 1998; Wavrant-DeVrieze et al., 1999; Christoforidis et al., 2005), others have shown weak or no such association (Beffert et al., 1999; Bertram et al., 2000; Pritchard et al., 2005; Harold et al., 2009; Lambert et al., 2009; Bertram et al., 2010; Chalmers et al., 2010; Natunen et al., 2012).”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“However, other studies in different populations have failed to show this association (Sano et al., 1997; Luchsinger et al., 2003; Petersen et al., 2005; Galasko et al., 2012) and the collective results from clinical trials remain equivocal.”
ResultDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“…across the blood-brain barrier Aβ concentration in brain interstitial fluid (ISF) is regulated by its rate of production from APP (Selkoe, 2001a; Cirrito et al., 2003) and clearance from brain (Mawuenyega et al., 2010) and across the BBB mainly via LRP1 (Shibata et al., 2000; Deane et al., 2004a).”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“…has been found to be increased in brain endothelial cells and vascular smooth muscle cells in animal models of aging as well as in AD patients (Yan et al., 1996; Deane et al., 2003; Donahue et al.,2006; Miller et al., 2008; Silverberg et al., 2010b), whereas LRP1 expression is decreased both…”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“However, other studies in different populations have failed to show this association (Sano et al., 1997; Luchsinger et al., 2003; Petersen et al., 2005; Galasko et al., 2012) and the collective results from clinical trials remain equivocal.”
ResultRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Self-citationBell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448 · cited 1×
“For instance, recent findings indicated that pericytes are critical for maintaining the BBB integrity (Bell et al., 2010), and that the inability of astrocyte-secreted apoE (i.e., apoE4) to interact with LRP1 on pericytes may lead to BBB breakdown and microvascular degeneration followed by…”
BackgroundSelf-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 11×
“…degradation, it has been also reported that LRP1 transports several ligands transcellularly across the blood-brain barrier (BBB) including Aβ (Shibata et al., 2000; Deane et al., 2004a; Davis et al., 2004; Wu et al., 2005; Cirrito et al., 2005; Bell et al., 2007), RAP (Pan et al., 2004),…”
BackgroundMethodInfluentialAn in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus
Pereira, A. C., Huddleston, D. E., Brickman, A. M., Sosunov, A. A., Hen, R., McKhann, G. M., Sloan, R., Gage, F. H., Brown, T. R., & Small, S. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611721104 · Cited by 1,353 · cited 2×
“Physical activity bolsters cerebral angiogenesis in rodents (Isaacs et al., 1992; Swain et al., 2003; Pereira et al., 2007; Latimer et al., 2011) and human subjects (Pereira et al., 2007) and may delay cognitive decline by reducing cerebrovascular risk, including the contribution of small vessel…”
BackgroundExcess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296 · cited 1×
“Lifestyle changes: Prevention—Cerebral oxidative stress is increased in AD (Smith et al., 1991; Montine et al., 2002; Lovell & Markesbery, 2007), and could render BBB LRP1 dysfunctional as a result of oxidation and/or reduced proteosomal degradation (Deane et al., 2004a).”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 3×
“However, the role of LRP1 in maintaining the integrity of the BBB has been recently demonstrated (Bell et al., 2012).”
BackgroundSelf-citationEffects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial
Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Plymate, S. R., Fishel, M. A., Watson, G. S., Cholerton, B. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.307 · Cited by 1,171 · cited 1×
“…a larger surface area for transport of molecules across the BBB. Recent studies have shown beneficial effects of physical activity on cognition in older adults (Lautenschlager et al., 2008; Middleton et al., 2008; Baker et al., 2010; Ahlskog et al., 2011; Graff-Radford, 2011; Tseng et al., 2011).”
BackgroundDietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972 · cited 1×
“…reduce the risk of AD (Jick et al., 2000; Wolozin et al., 2007), but prospective studies and clinical trials have produced inconsistent data (Di Paolo & Kim, 2011) with some showing reduced risk (Wolozin et al., 2000; Cramer et al., 2008; Sparks et al., 2008; Haag et al., 2009) and others…”
BackgroundGene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“The capsid amino acid sequence for AAV serotypes are different, except 1 and 6 (Daya & Berns, 2008), and may contribute to host cell specificity.”
BackgroundEnvironmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice
Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., Hersh, L. B., Sapolsky, R. M., Mirnics, K., & Sisodia, S. S. (2005) · Cell · doi:10.1016/j.cell.2005.01.015 · Cited by 885
Physical Exercise as a Preventive or Disease-Modifying Treatment of Dementia and Brain Aging
Ahlskog, J. E., Geda, Y. E., Graff-Radford, N. R., & Petersen, R. C. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0252 · Cited by 885
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 1×
“More studies are needed, however, to clarify the exact role of LRP1 in vascular dementia Some studies have shown that BBB is leakier in AD patients than in age-matched controls (Zipser et al., 2007; Farrall & Wardlaw, 2009).”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citationThe amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 9×
“…of Aβ to LRP1 at the abluminal brain endothelial cell membrane initiates rapid Aβ clearance across the BBB into the blood in vivo (Shibata et al., 2000; Deane et al., 2004a; Cirrito et al., 2005; Ito et al., 2006; Sagare et al., 2007; Bell et al., 2007; Deane et al., 2008; Bell et al., 2009).”
BackgroundMethodInfluentialSelf-citationMidlife vascular risk factors and late-life mild cognitive impairment: A population-based study
Kivipelto, M., Helkala, E.-L., Hänninen, T., Laakso, M. P., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · Neurology · doi:10.1212/wnl.56.12.1683 · Cited by 717
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678 · cited 1×
“A higher intake of vitamin C and E (Masaki et al., 2000; Engelhart et al., 2002; Zandi et al., 2004) and vitamin E (Morris et al., 2002) have been shown in some studies to be associated with a Pharmacol Ther.”
BackgroundBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 7×
“…of Aβ to LRP1 at the abluminal brain endothelial cell membrane initiates rapid Aβ clearance across the BBB into the blood in vivo (Shibata et al., 2000; Deane et al., 2004a; Cirrito et al., 2005; Ito et al., 2006; Sagare et al., 2007; Bell et al., 2007; Deane et al., 2008; Bell et al., 2009).”
BackgroundInfluentialSelf-citationCirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · cited 3×
“…in mice; LRP1 levels in AD brains Mice: WT, LDLR-/-, VLDLR-/-, RAP-/-; AD brains Deane et al., 2004 BBB Aβ clearance Mice: WT and AD mouse model Cirrito et al., 2005 LRP1/RAGE distribution Controls and AD brains Donahue et al., 2006 BBB Aβ clearance Rats Ito et al., 2006 Liver Aβ…”
BackgroundSwain, R. A., Harris, A. B., Wiener, E. C., Dutka, M. V., Morris, H. D., Theien, B. E., Konda, S., Engberg, K., Lauterbur, P. C., & Greenough, W. T. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00664-4 · Cited by 655
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 2×
“In contrast, RAGE mediates transport of blood-borne Aβ into brain and is associated with oxidant stress and pro-inflammatory response (Mackic et al., 1998a; Deane et al., 2003; Deane et al., 2012).”
BackgroundSelf-citationBlueberry supplementation improves memory in older adults
Krikorian, R., Shidler, M. D., Nash, T. A., Kalt, W., Vinqvist-Tymchuk, M. R., Shukitt-Hale, B., & Joseph, J. A. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf9029332 · Cited by 582 · cited 1×
“Some preliminary studies suggest that diet supplemented with polyphenols improves memory in older adults (Krikorian et al., 2010a; Krikorian et al., 2010b).”
BackgroundApolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · cited 2×
“It has been suggested that LRP1 in VSMC (Bell et al., 2009) and astrocytes (Koistinaho et al., 2004) participates in Aβ clearance.”
BackgroundDemeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · cited 2×
“…Herz & Strickland, 2001; Croy et al., 2003; Lillis et al., 2008; Meijer et al., 2007; Herz et al., 2009; Boucher & Herz, 2011), Alzheimer's amyloid-Aβ (Aβ) (Deane et al., 2004a; Sagare et al., 2007), prion protein (Parkyn et al., 2008; Jen et al., 2010) and aprotinin (Demeule et al., 2008a; 2008b).”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“The indirect targeting involves associating molecules that interact with both viral surface and the specific cell surface receptor such as antibodies (Bartlett et al., 2000) and biotin (Ponnazhagan et al., 2002).”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“However, viral based systems are usually more effective in mediating cell entry and transfer of genes to the target cell and are in many instances preferred (Davidson et al., 2000).”
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 1×
“It has also been demonstrated that LRP1 in neurons mediates Aβ cellular uptake and possibly retention in the brain via its ligands α2M and apoE (Narita et al., 1997; Qiu et al., 1999; DeMattos et al., 2004; Zerbinatti et al., 2004; Zerbinatti & Bu, 2005; Deane et al., 2008).”
Mucke, L. (2009) · Nature · doi:10.1038/461895a · Cited by 456
Gotthardt, M., Trommsdorff, M., Nevitt, M. F., Shelton, J., Richardson, J. A., Stockinger, W., Nimpf, J., & Herz, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000955200 · Cited by 450 · cited 11×
“…D Derocq et al., 2011 Adaptor/scaffold proteins that bind to the intracellular domain of the light chain Disabled-1 (Dab1) Trommsdorff et al., 1998; Gotthardt et al., 2000 Shc Barnes et al., 2001; Loukinova et al., 2002 PKCα Ranganathan et al., 2004 JIP1, JIP2 Gotthardt et al., 2000 Talin-like…”
BackgroundInfluentialWilliams, R. J., & Spencer, J. P. E. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.09.010 · Cited by 448 · cited 1×
“Therefore, enhancing the body's natural anti-oxidant defense mechanisms, with antioxidant nutrients, such as polyphenol-rich foods (Williams & Spencer, 2012; Hwang et al., 2012), vitamin A, C and E, could potentially protect LRP1 from oxidative damage, and thus reduce associated declines in Aβ…”
BackgroundRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study
Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., Sekita, A., Suzuki, S. O., Kanba, S., Kiyohara, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181eee25f · Cited by 432
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · cited 1×
“However, other studies in different populations have failed to show this association (Sano et al., 1997; Luchsinger et al., 2003; Petersen et al., 2005; Galasko et al., 2012) and the collective results from clinical trials remain equivocal.”
ResultIsaacs, K. R., Anderson, B. J., Alcantara, A. A., Black, J. E., & Greenough, W. T. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.14 · Cited by 405 · cited 1×
“Physical activity bolsters cerebral angiogenesis in rodents (Isaacs et al., 1992; Swain et al., 2003; Pereira et al., 2007; Latimer et al., 2011) and human subjects (Pereira et al., 2007) and may delay cognitive decline by reducing cerebrovascular risk, including the contribution of small vessel…”
BackgroundCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394 · cited 1×
“…across the blood-brain barrier Aβ concentration in brain interstitial fluid (ISF) is regulated by its rate of production from APP (Selkoe, 2001a; Cirrito et al., 2003) and clearance from brain (Mawuenyega et al., 2010) and across the BBB mainly via LRP1 (Shibata et al., 2000; Deane et al.,…”
BackgroundHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 2×
“…produced inconsistent data (Di Paolo & Kim, 2011) with some showing reduced risk (Wolozin et al., 2000; Cramer et al., 2008; Sparks et al., 2008; Haag et al., 2009) and others showing no change (Rea et al., 2005; Zandi et al., 2005; McGuinness et al., 2009; Benito-Leon et al., 2010; Feldman et…”
BackgroundDeane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Self-citationSehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390 · cited 4×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Table 3 LRP1 as a major Aβ clearance receptor Studies Models References BBB Aβ clearance Mice: WT and aging Shibata et al., 2000 LRP1-mediated Aβ internalization In vitro model (fibroblast cells); AD brains Kang et al., 2000 BBB Aβ cle…”
BackgroundInfluentialGalasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377 · cited 1×
“However, other studies in different populations have failed to show this association (Sano et al., 1997; Luchsinger et al., 2003; Petersen et al., 2005; Galasko et al., 2012) and the collective results from clinical trials remain equivocal.”
ResultDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 1×
“…that LRP1 transports several ligands transcellularly across the blood-brain barrier (BBB) including Aβ (Shibata et al., 2000; Deane et al., 2004a; Davis et al., 2004; Wu et al., 2005; Cirrito et al., 2005; Bell et al., 2007), RAP (Pan et al., 2004), tPA (Benchenane et al., 2005), lipid free and…”
BackgroundSelf-citationProteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368 · cited 1×
“The enzymatic degradation of Aβ may also contribute to its clearance from brain (Selkoe, 2001b; Saido & Leissring, 2012).”
BackgroundKang, D. E., Pietrzik, C. U., Baum, L., Chevallier, N., Merriam, D. E., Kounnas, M. Z., Wagner, S. L., Troncoso, J. C., Kawas, C. H., Katzman, R., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11013 · Cited by 354
Krikorian, R., Nash, T. A., Shidler, M. D., Shukitt-Hale, B., & Joseph, J. A. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114509992364 · Cited by 353
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351 · cited 2×
“…from blood to brain across the BBB of several species that have been studied including guinea-pigs, mice, rats and primates (Zlokovic et al., 1993; Ghilardi et al., 1996; Martel et al., 1996; Poduslo et al., 1997; Mackic et al., 1998b; Mackic et al., 2002; Ujiie et al., 2003; Eisele et al., 2010).”
BackgroundJaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., Shah, G. N., Price, T. O., Fleegal-Demotta, M. A., Butterfiled, D. A., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.01.017 · Cited by 281 · cited 1×
“…In vitro model: bEND.3 cells Yan et al., 2008 Brain vascular Aβ clearance WT mice, AD mouse models Bell et al. 2009 BBB Aβ clearance WT mice, LRP1 antisense Jaeger et al., 2009 BBB Aβ clearance Streptozotocin-induced diabetic mice Hong et al., 2009 Statin and LRP1 expression WT mice and in…”
BackgroundRole of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Self-citationSRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261 · cited 9×
“…risk factors and/or develop vascular changes in brain (i.e., > 65% of cases over the age of 60 and > 85% of cases over 80) (Wu et al., 2005; Bell et al., 2009; Zlokovic, 2011), it remains elusive whether MCI patients who later develop vascular dementia without amyloid deposition can also…”
BackgroundInfluentialSelf-citationZlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Self-citationThe Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate
von Arnim, C. A. F., Kinoshita, A., Peltan, I. D., Tangredi, M. M., Herl, L., Lee, B. M., Spoelgen, R., Hshieh, T. T., Ranganathan, S., Battey, F. D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414248200 · Cited by 258
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242 · cited 4×
“…from blood to brain across the BBB of several species that have been studied including guinea-pigs, mice, rats and primates (Zlokovic et al., 1993; Ghilardi et al., 1996; Martel et al., 1996; Poduslo et al., 1997; Mackic et al., 1998b; Mackic et al., 2002; Ujiie et al., 2003; Eisele et al., 2010).”
BackgroundInfluentialHippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease
Miller, M. C., Tavares, R., Johanson, C. E., Hovanesian, V., Donahue, J. E., Gonzalez, L., Silverberg, G. D., & Stopa, E. G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.124 · Cited by 194 · cited 2×
“…and vascular smooth muscle cells in animal models of aging as well as in AD patients (Yan et al., 1996; Deane et al., 2003; Donahue et al.,2006; Miller et al., 2008; Silverberg et al., 2010b), whereas LRP1 expression is decreased both at the BBB and in cerebral arterial vascular smooth muscle…”
BackgroundStatins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging
Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191 · cited 4×
“Targeting BBB LRP1 LRP1 expression at the BBB is reduced during normal aging and in AD (Kang et al. 2000; Shibata et al., 2000; Bading et al., 2002; Deane et al., 2004a; Donahue et al., 2006; Silverberg et al., 2010a).”
BackgroundInfluentialClearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159 · cited 1×
“LRP1 is highly expressed in hepatocytes serving as a cargo transporter of many macromolecules, including chylomicron remnants (Willnow et al., 1994; Mahley & Huang, 2007), α2 macroglobulin (Willnow et al., 1995; Poller et al., 1995), serine protease inhibitors (serpin)enzyme complex (Kounnas et…”
BackgroundMartel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149
Zerbinatti, C. V., Wozniak, D. F., Cirrito, J., Cam, J. A., Osaka, H., Bales, K. R., Zhuo, M., Paul, S. M., Holtzman, D. M., & Bu, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305803101 · Cited by 133 · cited 1×
“It has also been demonstrated that LRP1 in neurons mediates Aβ cellular uptake and possibly retention in the brain via its ligands α2M and apoE (Narita et al., 1997; Qiu et al., 1999; DeMattos et al., 2004; Zerbinatti et al., 2004; Zerbinatti & Bu, 2005; Deane et al., 2008).”
BackgroundSignaling through LRP1: Protection from atherosclerosis and beyond
Boucher, P., & Herz, J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.09.018 · Cited by 122 · cited 4×
“Introduction The low-density lipoprotein receptor (LDLR)-related protein 1 (LRP1/CD91/α2macroglobulin receptor), a member of the LDL receptor family, is a multifunctional scavenger, cargo transporter and signaling receptor (Dieckmann et al., 2010; Boucher & Herz, 2011).”
BackgroundInfluentialTamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Tamaki, C., Ohtsuki, S., & Terasaki, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.036913 · Cited by 111
Neurovascular Pathways and Alzheimer Amyloid β-peptide
Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00103.x · Cited by 104
Self-citationIto, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85
Mann, G. E., Zlokovic, B. V., & Yudilevich, D. L. (1985) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(85)90179-8 · Cited by 84
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Self-citationBlood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller-Salvia, B., Sánchez-Navarro, M., Giralt, E., & Teixidó, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 442
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Metadata
- Authors
- Sagare, A. P., Deane, R., & Zlokovic, B. V.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 136
- Issue
- 1
- Pages
- 94-105
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2085974856
- Cited by
- 143
- References
- 75
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.